Nas­daq threat­ens to delist Taysha Gene Ther­a­pies

Taysha Gene Ther­a­pies, a com­pa­ny that shelved a lengthy list of drug pro­grams and gen­er­at­ed con­tro­ver­sy by thwart­ing fam­i­ly-led re­boots, has re­ceived a delist­ing warn­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER